JDD Online’s Post

📢 New Publication: “Structural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis” recently published in Journal of Drugs in Dermatology (JDD). In this article, we summarize a work that explores the structural properties of IL-23 biologics and their correlation with clinical efficacy in treating moderate and severe plaque psoriasis. Key factors examined include epitope surface area, binding affinity, and dissociation rates, which help explain why some biologics outperform others. Key findings: Risankizumab has the largest epitope surface area, stronger binding affinity and higher PASI-90 response rates compared to other IL-23 inhibitors. Clinical Implications: 1- Drug selection: These insights may assist clinicians in choosing biologics for patients who require robust efficacy and less frequent dosing. 2- Biologic switching: For patients not responding to one IL-23 inhibitor, switching to another, such as risankizumab, might still be effective due to distinct molecular characteristics. The study contributes to a deeper understanding of IL-23 biologics and their role in optimizing psoriasis treatment strategies. #Psoriasis #Dermatology #IL23 #Biologics #Research #Insights

Why Are Some IL-23 Biologics More Effective for Psoriasis? Dive into the molecular mechanisms behind IL-23 biologics and discover what sets certain treatments apart in managing moderate to severe psoriasis. This new article from the Journal of Drugs in Dermatology breaks down key structural insights that could impact your clinical decisions. Stay ahead in the evolving world of biologics and optimize care for your patients. Read the full article now: 🔗 https://lnkd.in/eQWtdSAi #Dermatology #Psoriasis #Biologics #IL23 #ClinicalDerm #JDD #MedicalResearch

🚀 Exciting Growth in the Prescription Dermatology Therapeutics Market! 🚀 Get More Details: https://shorturl.at/x32tM The #Prescription #Dermatology #Therapeutics Market is projected to reach an impressive $79.11 billion by the end of the forecast period, growing at a robust CAGR of 9.5%. 🌟 Key drivers for this growth include: 🔹 High incidence and prevalence of infectious and chronic dermatological disorders. 🔹 Continuous novel drug development worldwide. Our skin, the body's largest and most exposed organ, faces constant threats from various toxins and microbes. This highlights the critical need for advanced dermatological treatments. Stay tuned for more updates on how this dynamic market is evolving! Prescription Dermatology Therapeutics Market, Key Players are: AbbVie Janssen Biotech, Inc. Novartis Amgen #Dermatology #Healthcare #Pharmaceuticals #MarketGrowth #Innovation

🗞 AFR Article Did you catch us in The Australian Financial Review? Markets Reporter Joanne Tran published an article, ‘This media company’s share price is tipped to double’, which called out Botanix Pharmaceuticals as an ASX favourite. Lennox Capital Partners’s Liam Donohue assessed the market opportunity for Sofdra™: ‘… current treatments have been more invasive (such as targeted Botox injections) and typically less effective. ‘So, with many of the more binary risks out of the way for Botanix, we think the opportunity in front of the company is immense. That is especially the case when you couple this with management’s history of commercialising pharma products in the US.’ Read the full article 👉 https://bit.ly/3E45fvj $BOT #ASX #pharma #innovation #dermatology #hyperhidrosis #FDA #AFR

Read the blog: https://ow.ly/tthf50SPm2Q Discover the latest insights in psoriasis treatment with our new blog post: “A Matching-Adjusted Indirect Comparison (MAIC) of Guselkumab Versus Risankizumab in Patients With Moderate-to-Severe Plaque Psoriasis” by Barkha Patel, PhD and Tim Disher. This study emphasizes the importance of ITCs in guiding optimal treatment strategies for PsO. Dive deeper into the findings and their implications for clinical decision-making. #Psoriasis #Dermatology #Biologics #Guselkumab #Risankizumab #HEOR #ClinicalInsights #MAIC

We were privileged to host Dr. Gurpreet Ahluwalia, Vice President of Clinical Development at Enveda Biosciences, for an engaging session in our Guest Speaker Series! His presentation provided a comprehensive look at the pharmaceutical drug development process, with a special focus on dermatology. 🔑 Key takeaways from the session: ✅”Safety first" was emphasized as the cornerstone of drug development, highlighting the regulatory safeguards at every stage—preclinical, clinical, and beyond. ✅The importance of a diverse workforce and patient population to ensure clinical trials are inclusive and representative. ✅Clinical research as a clean and impactful profession, offering unparalleled satisfaction when a drug you worked on reaches the market and helps countless patients. We look forward to many more insightful sessions with industry experts in the future. If you are not yet part of our network, join our community today! #sikhsinclinicalresearch #clinicalesearch #drugdevelopment #dermatology #skincare #medicine #publichealth #diversitymatters #pharmaceuticalIndustry #clinicaltrials #researchliteracy #patientadvocacy #career

Join Genemarkers’ Anna Langerveld and Jocelyn K. at the 8th Annual Dermatology Drug Development Summit on November 12-14, 2024 in Boston.  This is a great opportunity to learn how Genemarkers’ services can improve your drug development. To connect with Anna and Jocelyn during the event, email jkearsley@genemarkersllc.com or schedule a meeting directly: https://lnkd.in/ePKXEseV #Dermatology #Dermatologics  #DermatologyMedication #TopicalDermatology #DermatologyDrug #DrugDevelopment #Pharma #Pharmaceuticals #SkinScience #Skincare #DermalPharma #DermalResearch #DrugDiscovery #Preclinical #PreclinicalResearch #ClinicalTrial #ClinicalResearch

Don't miss our live 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗼𝗻 𝗗𝗲𝗿𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝘆 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 & 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁! 👉 REGISTER HERE: https://lnkd.in/eR_P94BN #drugdevelopment #dermatology #pharma #webinar

With more than 20 completed dermatology studies, AutoCruitment is one of the leaders in patient recruitment for dermatological conditions. #dermatology #clinicaltrials #clinicalresearch #patientrecruitment #biopharmaceutical #lifesciences #biotech #pharmaceutical